SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Oncothyreon
An SI Board Since September 1996
Posts SubjectMarks Bans Symbol
2344 74 0 ONTY
Emcee:  John Curtis Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2194Too few pts out beyond 50 months for both groups, especially in the placebo groubiomachine56-6/6/2013
2193Rick -- Agree 100% on 380. Years down the road. At least for 2013 does not incregeneguru-6/5/2013
2192>> INSPIRE modified to enroll ONLY cCRT << investorvillage.com Thascaram(o)uche-6/5/2013
2191That was a good view of the company, solid presentation. A little too much 380 scaram(o)uche-6/5/2013
2190fwiw: AF Tweet: BiotechStockResearch ?@BiotechStockRsr 8h $onty PX-866 doesn&mopgcw-6/3/2013
2189Bad day to be busy/distracted. Once believed that 380 would be a core element oscaram(o)uche-5/30/2013
2188PX-866 Update The Company's randomized Phase 2 portion of its Phase 1/2 tribiomachine56-5/30/2013
2187SEATTLE and BOULDER, Colo., May 30, 2013 /PRNewswire/ -- Oncothyreon Inc. ( ONTYnigel bates-5/30/2013
2186Cetuximab in HSCCHN ncbi.nlm.nih.gov Mechanisms underlying resistance to cetuxbiomachine56-5/30/2013
2185Head and Neck cancer ncbi.nlm.nih.gov 1.2. Squamous cell carcinoma of the headbiomachine56-5/30/2013
2184PX-866 patent filings May 23, 2013 appft1.uspto.gov United States Patent Applbiomachine56-5/28/2013
2183PX866/CTX combo in mCRC is in refractory pts (failed irinotecan and oxaliplatin)biomachine56-5/28/2013
2182The ORR primary aside, the established PFS in CTX monotherapy in irinotecan/oxalbiomachine56-5/28/2013
2181Rick, Check your mail. Mbiomachine56-5/28/2013
2180Again, thanks for the good stuff. A few trading days, and we'll be through scaram(o)uche-5/28/2013
2179BKM120 is the other horse with PX-866. BKM120 appears to be a step behind on thbiomachine56-5/24/2013
2178Nice summary, thanks!scaram(o)uche-5/23/2013
2177The response rate in the FDA approval for CTX monotherapy was 6% in irinotecan abiomachine56-5/23/2013
2176>> BKM120 seems to have a wider range of toxicities, especially hyperglycescaram(o)uche-5/23/2013
2175Welcome BioMachine56! He is active poster on IV and knows his stuff. Interactiongeneguru-5/23/2013
2174Looks like NVP is pursuing BKM120 in mCRC and SCCHN in combo with CTX. What'biomachine56-5/23/2013
2173parking, hope it works..... abstractsearch.asco.orgscaram(o)uche-5/21/2013
2172The computers and large traders have the stock locked in a vice grip range....The Ox-5/21/2013
2171I'm in. Not going to be boring.nigel bates-5/21/2013
2170Steve, it's going to be tough to get a standing-room-only space at Butts'scaram(o)uche-5/21/2013
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News